CRCT - Centre de Recherches en Cancérologie de Toulouse
  • Center
    • Discover the Center
    • CRCT News
    • Annual report
    • Governance
    • Institutions and partners
    • Support services
    • The Scientific Events Committee
    • CRCT’s student activity
    • Directory
    • Publications
    • Events
    • Contact & Map
  • Research
    • Research lines and medico-scientific programs
      • General presentation medico scientific programs
      • Research lines
      • Medico-scientific programs
      • European programs
      • Seminars – CRCT
    • Research teams
      • M. Ayyoub
      • G. Favre / O. Sordet
      • B. Segui / N. Andrieu
      • S.Millevoi
      • C. Bousquet
    •  
      • S. Pyronnet / F. Meggetto
      • C. Laurent
      • P. Cordelier
      • E. Cohen-Jonathan Moyal / C. Toulas
      • M. Poirot / S. Silvente-Poirot
      • H. Avet-Loiseau / L. Martinet
    •  
      • E. Chatelut
      • E. Delabesse
      • J. Guillermet-Guibert
      • J.E. Sarry
      • F. Chibon
      • S. Valitutti
      • V. Pancaldi
  • CRCT/IUCT-O’s Programs
    • General aims of the programs
    • Our ongoing programs
  • Technology
    • General presentation technology
    • Technology Cluster’s website
  • Fr
  • En
Select Page
Reprogram a family of lipids to increase the efficacy of melanoma immunotherapy.

Reprogram a family of lipids to increase the efficacy of melanoma immunotherapy.

by Stephane Cailmail | 7 Apr 2021 | General news, Publications, Research

Immunotherapy for advanced melanoma has revolutionized the treatment of this deadly cancer. However, almost half of patients do not respond to this treatment and die within 5 years after starting treatment. Our work shows that melanoma cells exhibit alterations in the...
A new immunotherapy strategy in melanoma patients.

A new immunotherapy strategy in melanoma patients.

by Stephane Cailmail | 11 Mar 2021 | General news, Publications, Research

Melanoma is a bad-prognosis skin cancer generally treated with monoclonal antibodies that neutralize immune checkpoints such as anti-CTLA-4 (ipilimumab) or anti-PD-1 (nivolumab). Unfortunately, a significant proportion of patients do not respond to these treatments....
Interest of DPD deficiency testing in all patients receiving fluoropyrimidines for cancer treatment.

Interest of DPD deficiency testing in all patients receiving fluoropyrimidines for cancer treatment.

by Stephane Cailmail | 8 Mar 2021 | General news, Publications, Research

Fluoropyrimidines (including 5-fluorouracil and its prodrug capecitabine) can cause serious adverse events related to a dihydropyrimidine dehydrogenase (DPD) deficiency, the enzyme involved in the degradation of 5-FU. This study reports the case of a patient treated...
Rapid and sensitive detection of biomarkers of interest in cancerology

Rapid and sensitive detection of biomarkers of interest in cancerology

by Stephane Cailmail | 16 Feb 2021 | General news, Publications, Research

MicroRNAs are short non-coding RNA sequences whose expression is deregulated in cancers. In particular, miR-21 microRNA is a promising biomarker for the diagnosis and the monitoring of patients with pancreatic cancer. In this work, we use the µLAS microfluidic...
A novel imaging approach for single-cell, real-time analysis of oncolytic virus replication and efficacy in cancer cells

A novel imaging approach for single-cell, real-time analysis of oncolytic virus replication and efficacy in cancer cells

by Stephane Cailmail | 12 Feb 2021 | General news, Publications, Research

Oncolytic viruses infect and replicate in cancer cells to induce cell death. As such, they are promising new therapies against cancer. This study describes for the first time the antitumor activity of SG33, a veterinary vaccine strain derived from the Myxoma virus....
Normalization of protein secretion in tumour microenvironment inhibits metastasis development in pancreatic cancer

Normalization of protein secretion in tumour microenvironment inhibits metastasis development in pancreatic cancer

by Stephane Cailmail | 8 Feb 2021 | General news, Publications, Research

Fibroblasts present in pancreatic tumours produce large amounts of proteins, which promote the proliferation of cancer cells, as well as their ability to metastasize. We have shown that these fibroblasts can be targeted using a somatostatin analogue SOM230, a molecule...
« Older Entries

News

  • Reprogram a family of lipids to increase the efficacy of melanoma immunotherapy.
  • Rapid detection of a cancer biomarker by a microfluidic chip
  • The cell signalling enzymes PI3Kalpha and PI3Kβ play major roles in the body.
  • A new immunotherapy strategy in melanoma patients.
  • Interest of DPD deficiency testing in all patients receiving fluoropyrimidines for cancer treatment.
  • Contact & Map
  • Legal statements
  • RSS
© Conception & Design Agence CosiWeb